

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/574,645

Confirmation No. 9318

Applicant: Salomon et al.

Filed: August 10, 2006

TC/AU: 1634

Examiner: Steven C. Pohnert

Docket No.: 251206 (Client Reference No. E-075-2003/0-US-03)

Customer No.: 45733

DECLARATION UNDER 37 C.F.R. § 1.132 OF NANCY E. J. BERMAN, PH.D.

I, Nancy E. J. Berman, Ph.D., do hereby declare:

1. I am a co-inventor of the subject matter disclosed and claimed in the above-captioned patent application ("the present application"), which I understand was filed as International Application PCT/US04/32649 on October 1, 2004. I am aware of the general knowledge available in the art and of the skill level of the ordinary artisan as it exists today and as it existed at the time the present patent application was filed.
2. It is my understanding that claim 1 of the present application is directed to detecting NeuroAIDS in a mammal by assaying the expression level of Cripto-1.
3. I have reviewed the Final Office Action, dated September 12, 2008, and the Advisory Action, dated December 30, 2008, from the U.S. Patent and Trademark Office (USPTO) regarding the present application. I understand that the USPTO has rejected the pending claims of the present application because the USPTO does not consider that the present application enables methods of detecting NeuroAIDS in a mammal by assaying the expression level of Cripto-1.
4. The USPTO alleges that (i) the study only used a single control and, essentially, the study cannot be used to determine indication of a disease due to a small control sample size, (ii) post-exsanguination collection of tissue cannot be used to reliably determine gene expression, (iii) the model system detected the macaque homologue of the

human sequence (SEQ ID NO: 1) of Cripto-1 and would not detect human Cripto-1, (iv) there were no studies performed in humans, (v) the macaque monkey is not a reasonable model for humans and SHIV infection is not a reasonable model for NeuroAIDS, (vi) there is no nexus for the role of increased SEQ ID NO: 1 and NeuroAIDS, (vii) Raghaven et al., Brain Pathol., 7:851-861 (1997) ("Raghaven") teaches SHIV has different affects on two members of the macaque family and that SIV- and SHIV-induced NeuroAIDS have different pathologies, and (viii) Enard et al., Science, 296:340-343 (2002) ("Enard") teaches intra- and interspecies variation in gene expression in brain tissue is substantial and Cheung et al., Nat. Genet., 33:422-425 (2003) ("Cheung") teaches there is natural variation in gene expression among different individuals and renders unpredictable any correlation between altered gene expression and phenotype.

5. The USPTO also alleges that (i) knowledge of the particular housekeeping genes used in a gene expression study is required, (ii) Vandesompele et al., Genome Biol., 3:1-11 (2002) ("Vandesompele") teaches at least three housekeeping genes are required for accurate normalization of gene expression data and that using one gene for normalization is not reliable due to large variation in housekeeping gene expression, (iii) Wu, J. Pathol., 195: 53-65 (2001) ("Wu") teaches that conclusions drawn from gene expression data depend heavily on the particular choice of data analysis, and (iv) Newton et al., J. Comput. Biol., 8:37-52 (2001) ("Newton") teaches that a basic statistical problem is determining when the measured differential expression is likely to reflect a real biological shift in gene expression, and replication of data is critical to validation.

6. Macaque monkey studies are necessarily constrained by expense and housing considerations. Individual macaque monkeys are much more expensive than individual mice, rats, etc. used for animal model studies. Also, macaque monkeys require more housing space than, e.g., mice or rats, and require more specialized facilities than those necessary for these mammals. The specialized facilities, then, also further increase the cost of performing macaque studies compared to performing studies on other mammals commonly used for animal model studies. Due to the expense and specialized facilities required, it was accepted in the art at the time of filing the present application that macaque monkey studies were necessarily on a smaller scale than studies with, e.g., mice or rats. Although other macaque studies have used higher numbers of controls, such studies were still routinely performed on a small number of test macaque monkeys, including using one macaque monkey as a control.

7. Post-exanguination collection of tissue is a reliable method for collecting tissue samples for gene expression analysis. Although post-exanguination may produce unreliable gene expression data if it is performed incorrectly, the method was an accepted practice in animal model studies at the time of filing the present application and provides reliable results when performed carefully. For the present application, the post-exanguination collection of tissue was performed carefully to ensure reliable results.

8. One of ordinary skill in the art would have recognized at the time of filing the present application that primers derived from the human sequence of Cripto-1 (SEQ ID NO: 1) would identify gene expression of macaque Cripto-1 in a macaque animal model. When the macaque studies described in the present application were performed, the expressed gene, identified by human-derived primers, was cloned and identified as macaque Cripto-1. Although macaque and human Cripto-1 are not identical, for the reasons set forth below, one of ordinary skill in the art would have recognized at the time of filing the present application that identification of macaque Cripto-1 in a macaque NeuroAIDS animal model would have been indicative of identification of human Cripto-1 (SEQ ID NO: 1) in a human patient suffering from NeuroAIDS since the macaque monkey animal model was an acceptable animal model of human NeuroAIDS.

9. Studies of altered gene expression in humans presents many obstacles that are overcome when using animal models. For example, NeuroAIDS may be induced in animals to provide specific research conditions; and should more studies be needed, more animals may be induced to develop NeuroAIDS. Also, the extraction of central nervous tissue from humans should not be performed unless absolutely necessary, e.g., after the development of a reliable assay in an animal model, such as that described in the present application. Prior to the development of such an assay, extraction of central nervous tissue would be overly invasive and would not likely be justified.

10. At the time of filing the present application, the macaque monkey animal model was an acceptable animal model for studying NeuroAIDS in humans. The results described in the Examples of the present application were published, after filing the application, as Stephens et al., *Neurosci. Lett.*, 410:94-99 (2006) ("Stephens"). The methods used in the present application and in Stephens also were used in Buch et al., *J. Neuroimmunol.*, 157:71-80 (2004) ("Buch") and Sui et al., *J. Med. Primatol.*, 32:229-239

(2003) ("Sui"), which were published at around the same time as the filing of the present application. These studies used macaque monkeys to investigate gene expression in brain tissue after induction of HIV-related encephalitis.

11. The function of a gene or its role in a disease-state need not be known for alteration of its expression to indicate the existence of that disease-state. Therefore, even though no nexus is provided between a particular gene and a disease-state, the altered expression of the gene may be indicative of the presence of the disease-state. As was shown in the present application, upregulation of Cripto-1 in nervous tissue is indicative of NeuroAIDS.

12. Although the neuropathogenesis of SHIV in pig-tailed and rhesus macaques may be different, this difference, as described in Raghaven, is due to activation of the virus in rhesus macaque versus pig-tailed macaque. Raghaven is silent as to whether the activation or non-activation of SHIV alters Cripto-1 expression. Therefore, non-activation of SHIV in pig-tailed macaque as described in Raghaven does not in itself foreclose the possibility of upregulation of Cripto-1. Also, the SHIV used in the present application is SHIV 50OLNV, a SHIV strain that, as shown in the present application, is activated in pig-tailed macaques (see Example 1 of the present application).

13. Intra- and interspecies variations, as described in Enard and Cheung, certainly exist. However, one of ordinary skill in the art would have recognized at the time of filing the present application that the SHIV macaque model was an acceptable model to model the effects of NeuroAIDS in humans. Therefore, one of ordinary skill in the art would have recognized that the altered gene expression observed in the SHIV macaque models used in the present application are indicative of altered gene expression due to NeuroAIDS in humans.

14. The methods of detection used in the present application were the accepted methods of ordinary artisans at the time of filing the present application. First, one of ordinary skill in the art would have easily identified housekeeping genes for use in gene expression studies such as the ones described in the present application. Housekeeping genes are defined as those that do not have altered expression under the experimental conditions tested. Therefore, identification of which particular housekeeping genes were used in any

gene expression study is not necessary. Furthermore, other papers published around the time of the filing of the present application (Buch and Sui) also used methods similar to those of the present application to determine altered gene expression in macaque model systems. Additionally, the methods of Wu and Newton describe microarray experiments, particularly Affymetrix microarrays. I am not aware of any macaque Affymetrix microarray system that was available when the studies of the present application were performed since, to my knowledge, the macaque genome had not been sequenced. Therefore, to my knowledge, the methods described in these articles did not represent the commonly used practice in the art (for macaque model systems) at the time of filing the present application and thus would have been inappropriate to analyze the data of the present application. Additionally, the CLOTECH software used in Newton normalizes the microarray to a set of nine housekeeping genes. However, using a single housekeeping gene for RT-PCR replication of microarray data is standard practice. Regarding Vandesompele, the procedure recommended in this paper has not become standard practice. Therefore, although Vandesompele, Wu, and Newton caution against particular methods of data analysis, one of ordinary skill in the art at the time the present application was filed would have recognized that the methods used in the present application were those accepted in the art.

15. Therefore, I believe that an ordinary artisan, upon reading the disclosure of the present application, would understand that the specification as filed enables methods of detecting NeuroAIDS in a mammal by assaying the expression level of Cripto-1.

16. I hereby declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: March 3, 2009 _____


Nancy E. J. Berman, Ph.D.